Celsion logo

CLSN - Celsion News Story

$1.37 -0.4  -21.3%

Last Trade - 22/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £37.5m
Enterprise Value £27.7m
Revenue £365k
Position in Universe 5289th / 6630

Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, 2020

Mon 9th November, 2020 1:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201109:nGNXYcKLn


LAWRENCEVILLE, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation
(NASDAQ: CLSN) announced today that the Company will host a conference call to
discuss financial results for the third quarter ended September 30, 2020 and
provide an update on its development programs for GEN-1, an IL-12 DNA plasmid
vector formulated into a nanoparticle with a non-viral delivery system and
ThermoDox(®), its proprietary heat-activated liposomal encapsulation of
doxorubicin at 11:00 a.m. ET on Monday, November 16, 2020.

To participate in the call, interested parties may dial 1-800-367-2403
(Toll-Free/North America) or 1-334-777-6978 (International/Toll) and ask for
the Celsion Corporation Third Quarter 2020 Earnings Call (Conference Code:
8337630) to register ten minutes before the call is scheduled to begin. The
call will also be broadcast live on the internet at www.celsion.com. The call
will be archived for replay on Monday, November 16, 2020 and will remain
available until November 30, 2020. The replay can be accessed at
1-719-457-0820 or 1-888-203-1112 using Conference ID: 8337630. An audio replay
of the call will also be available on the Company's website, www.celsion.com,
for 90 days after 2:00 p.m. ET Monday, November 16, 2020.

About Celsion Corporation

Celsion is a fully integrated oncology company focused on developing a
portfolio of innovative cancer treatments, including immunotherapies,
DNA-based therapies and directed chemotherapies. The Company’s product
pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment
of ovarian cancer and ThermoDox(®), a proprietary heat-activated liposomal
encapsulation of doxorubicin, currently in Phase III development for the
treatment of primary liver cancer and in development for other cancer
indications. Celsion has two feasibility stage platform technologies for the
development of novel nucleic acid-based immunotherapies and other anti-cancer
DNA or RNA therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For more
information on Celsion, visit: http://www.celsion.com. (CLSN-FIN).

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the uncertainties of and difficulties in
analyzing interim clinical data; the significant expense, time, and risk of
failure of conducting clinical trials; the need for Celsion to evaluate its
future development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to
time in Celsion's periodic reports and prospectuses filed with the Securities
and Exchange Commission. Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent events,
new information or otherwise.

Celsion Investor Contact                                   
                             LHA Investor Relations
 Jeffrey W. Church                                       
                                      Kim Sutton Golodetz
 Executive Vice President & CFO                               
                       212-838-3777
 609-482-2455                                           
                                        
kgolodetz@lhai.com
 jchurch@celsion.com

# # #



(https://www.globenewswire.com/NewsRoom/AttachmentNg/38ec2900-8f4f-40ac-9807-64be276aa13e)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.